Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX)
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
Atrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy?
Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX)
Results from Phase 1 Multiple-Dose Study of PT00114
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
Atrinsic (NASDAQ:PTIX) Trading Up 2.5% – Time to Buy?
Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting
Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
Protagenic Therapeutics Shares Increase Over 10% Pre-Market: Why It Happened
Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
7 Best Penny Stocks to Buy Now for Potential 10X Gains
PTIX Stock Price: Over 25% Increase Pre-Market Explanation
Best Biotech Penny Stocks in June 2021? Check These 4 Out
4 Biotech Penny Stocks That You Need to Know About
Market Update: The 10 Most Volatile Stocks Today
PTIX Stock: Over 80% Increase Intraday Explanation
Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering